Long-term follow-up of people treated with CS-101 for beta-thalassemia
Follows people with beta-thalassemia who received CS-101 gene-edited stem cells.
Plain-language title generated from the registry record
Registry title: A Long-term Follow-up Study in Participants Who Received CS-101
Key facts
- Where
- Nanning, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with β-thalassemia who already received CS-101 in the earlier study CS-101-06. It follows them over the long term. No new study drug is given.
- Age
- 6 Years to 35 Years
- Sex
- All sexes can join.
- Earlier treatment
- People must have received a CS-101 infusion in the earlier study.
Main reasons for not taking part
- The record lists no exclusion criteria.
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 35 years old?
Source: NCT06685536, who can take part
Where in China
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CorrectSequence Therapeutics Co., Ltd
- Trial code
- NCT06685536
- Record updated
- 10 February 2026
- Original description
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.Read full original descriptionShow less
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
Inclusion: Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form; Participants must have received CS-101 infusion in last study.
Exclusion: There are no exclusion criteria.